Phase 2/3 Heterologous Boosting Study With Different Dose Levels of Monovalent SARS-CoV-2 rS Vaccines
Public ClinicalTrials.gov record NCT05925127. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2/3, Randomized, Double-Blind Study to Evaluate the Safety and Immunogenicity of Different Booster Dose Levels of Monovalent SARS-CoV-2 rS Vaccines in Adults ≥ 50 Years Previously Vaccinated With COVID-19 mRNA Vaccines
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a Phase 2/3, randomized, double-blind study to evaluate the safety and immunogenicity of different booster dose levels of the monovalent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) recombinant (r) spike (S) protein nanoparticle (SARS-CoV-2 rS) vaccines with Matrix-M™ adjuvant (NVX-CoV2373 \[prototype Wuhan vaccine with Matrix-M adjuvant\] or NVX-CoV2601 \[Omicron XBB.1.5 subvariant vaccine with Matrix-M adjuvant\]).
Study identification
- NCT ID
- NCT05925127
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2, Phase 3
- Enrollment
- 994 participants
Conditions and interventions
Conditions
Interventions
- NVX-CoV2373 (5μg) Biological
- NVX-CoV2601(5μg) Biological
- NVX-CoV2601(35μg) Biological
- NVX-CoV2601(50μg) Biological
- Bivalent BA.4/5 Biological
Biological
Eligibility (public fields only)
- Age range
- 50 Years to 99 Years
- Sex
- All
- Healthy volunteers
- Accepts healthy volunteers
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 15, 2023
- Primary completion
- May 20, 2024
- Completion
- May 20, 2024
- Last update posted
- Dec 12, 2024
2023 – 2024
United States locations
- U.S. sites
- 50
- U.S. states
- 22
- U.S. cities
- 47
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| ARS-Birmingham CRU | Birmingham | Alabama | 35216 | — |
| Tucson Neuroscience Research | Tucson | Arizona | 85710 | — |
| Velocity Clinical Research, Banning | Banning | California | 99202 | — |
| Velocity Clinical Research, Chula Vista | Chula Vista | California | 91911 | — |
| Velocity Clinical Research, San Diego | La Mesa | California | 91942 | — |
| Artemis Institute for Clinical Research | Riverside | California | 92503 | — |
| Artemis - San Diego | San Diego | California | 92103 | — |
| WR-MCCR | San Diego | California | 92120 | — |
| Deland CRU | DeLand | Florida | 32720 | — |
| Health Awareness | Jupiter | Florida | 33458 | — |
| Wr-Msra, Llc | Lake City | Florida | 32055 | — |
| Professional Urgent Care Services | Largo | Florida | 33777 | — |
| Research Institute of South Florida | Miami | Florida | 33173 | — |
| Suncoast Research Associates, LLC | Miami | Florida | 33173 | — |
| Headlands Research Orlando LLC | Orlando | Florida | 32819 | — |
| Precision Clinical Research, LLC | Sunrise | Florida | 33351 | — |
| TrueBlue Clinical Research | Tampa | Florida | 33609 | — |
| Neurostudies CRU | Decatur | Georgia | 30030 | — |
| Velocity Clinical Research | Savannah | Georgia | 31406 | — |
| CRA Headlands LLC | Stockbridge | Georgia | 30281 | — |
| Velocity Clinical Research | Meridian | Idaho | 83642 | — |
| Velocity Clinical Research | Sioux City | Iowa | 51106 | — |
| Velocity Clinical Research | Baton Rouge | Louisiana | 70809 | — |
| Velocity Clinical Research - Covington | Covington | Louisiana | 70433 | — |
| Velocity Clinical Research, Metairie | Metairie | Louisiana | 70006 | — |
| Activmed Practices and Research, LLC | Methuen | Massachusetts | 01844 | — |
| Velocity Clinical Research, Gulfport | Gulfport | Mississippi | 39503 | — |
| Velocity Clinical Research | Grand Island | Nebraska | 68803 | — |
| Velocity Clinical Research | Norfolk | Nebraska | 68701 | — |
| Velocity Clinical Research | Omaha | Nebraska | 68134 | — |
| Activmed Practices and Research, LLC | Portsmouth | New Hampshire | 03801 | — |
| Velocity Clinical Research | Binghamton | New York | 13905 | — |
| Hypercore (Lucas Research) | New Bern | North Carolina | 28562 | — |
| M3 Wake Research Inc | Raleigh | North Carolina | 27612 | — |
| Trial Management Associates, LLC | Wilmington | North Carolina | 28403 | — |
| Javara Inc./Wake Forest Health Network, LLC | Winston-Salem | North Carolina | 27157 | — |
| Velocity Clinical Research | Cincinnati | Ohio | 45219 | — |
| Velocity Clinical Research | Cincinnati | Ohio | 45246 | — |
| Tekton Research | Edmond | Oklahoma | 73013 | — |
| Lynn Health Science Institute | Oklahoma City | Oklahoma | 73112 | — |
| Velocity Clinical Research, Grants Pass | Grants Pass | Oregon | 97527 | — |
| Velocity Clinical Research, Providence | East Greenwich | Rhode Island | 02818 | — |
| Velocity Clinical Research, Gaffney | Gaffney | South Carolina | 29340 | — |
| Coastal Carolina Research Center an ALCANZA Clinical Research company | North Charleston | South Carolina | 29405 | — |
| Central Texas Clinical Research, LLC | Austin | Texas | 78705 | — |
| Research Your Health | Plano | Texas | 75093 | — |
| Benchmark Research | San Angelo | Texas | 76904 | — |
| Velocity Clinical Research, Salt Lake City | West Jordan | Utah | 84088 | — |
| Health Research of Hampton Roads, Inc | Newport News | Virginia | 23606 | — |
| Clinical Research Partners | Richmond | Virginia | 23226 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05925127, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Dec 12, 2024 · Synced Sep 5, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT05925127 live on ClinicalTrials.gov.